Daily Anesthesiology Research Analysis
Three high-impact critical care studies relevant to anesthesiology and intensive care emerged: a multicenter RCT showed that a personalized capillary refill time–targeted resuscitation strategy modestly improved a hierarchical outcome in early septic shock; a large international cluster RCT found no mortality benefit of selective digestive decontamination (SDD) in ventilated ICU patients while raising ecological concerns; and a global, data-driven update of the SOFA score (SOFA-2) improved predi
Summary
Three high-impact critical care studies relevant to anesthesiology and intensive care emerged: a multicenter RCT showed that a personalized capillary refill time–targeted resuscitation strategy modestly improved a hierarchical outcome in early septic shock; a large international cluster RCT found no mortality benefit of selective digestive decontamination (SDD) in ventilated ICU patients while raising ecological concerns; and a global, data-driven update of the SOFA score (SOFA-2) improved predictive validity and modernized organ dysfunction thresholds.
Research Themes
- Personalized hemodynamic resuscitation in septic shock
- Infection control strategies and ecological impact in the ICU
- Modernization and validation of organ dysfunction scoring (SOFA-2)
Selected Articles
1. Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial.
In a 19-country multicenter RCT of early septic shock, a CRT-targeted personalized hemodynamic protocol achieved a significant win ratio (1.16) over usual care on a 28-day hierarchical composite outcome. The benefit was driven mainly by fewer days requiring vasoactive support, mechanical ventilation, and kidney replacement therapy.
Impact: This trial provides high-level evidence that a simple bedside perfusion target (CRT) embedded in a personalized protocol can improve clinically meaningful composite outcomes in septic shock.
Clinical Implications: Adopting CRT-guided personalized resuscitation may reduce exposure to vasoactives, ventilation, and kidney support in early septic shock. Implementation requires protocolized assessment of pulse pressure, diastolic pressure, fluid responsiveness, and point-of-care echocardiography.
Key Findings
- Win ratio of 1.16 (95% CI 1.02–1.33; P=0.04) favoring CRT-personalized resuscitation for the 28-day hierarchical composite.
- Primary benefit components: reduced duration of vital support (vasoactives, mechanical ventilation, kidney replacement therapy).
- Trial spanned 86 centers in 19 countries; stratification by APACHE II supported robustness across illness severity.
Methodological Strengths
- Multicenter randomized design with global enrollment and protocolized personalized assessment.
- Use of a hierarchical composite and win ratio to capture clinically meaningful differences beyond mortality alone.
Limitations
- Open-label pragmatic design with potential variability in usual care across centers.
- Effect largely on support duration; individual mortality differences were not the main driver.
Future Directions: Evaluate mortality-focused endpoints, cost-effectiveness, and integration with other perfusion/echocardiographic targets; assess implementation fidelity and training needs.
IMPORTANCE: The optimal strategy for hemodynamic resuscitation in early septic shock remains uncertain. OBJECTIVE: To determine the effect of a personalized hemodynamic resuscitation protocol targeting capillary refill time (CRT-PHR) on a hierarchical composite outcome of mortality, duration of vital support, and length of hospital stay. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted in 86 centers in 19 countries. Patients within the first 4 hours of septic shock were included between March 2022 and April 2025, with last follow-up in July 2025. INTERVENTIONS: Patients were randomized to undergo CRT-PHR (n = 720), including assessment of pulse pressure, diastolic arterial pressure, fluid responsiveness, and bedside echocardiography, to tailor fluids, vasopressors, and inotropes, vs usual care (n = 747). MAIN OUTCOMES AND MEASURES: The primary outcome was a hierarchical composite of mortality, duration of vital support (vasoactives, mechanical ventilation, and kidney replacement therapy), and length of hospital stay assessed at 28 days. A win ratio was calculated for the primary outcome by comparing all possible patient pairs, starting with the first event in the hierarchy and stratified by median APACHE (Acute Physiology and Chronic Health Evaluation) II score at admission. Secondary outcomes were mortality, vital support-free days, and length of hospital stay at 28 days. RESULTS: From 1501 randomized patients, 1467 were included in the primary analysis (mean age, 66 [17] years; 43.3% female). There were 131 131 wins (48.9%) in the CRT-PHR group vs 112 787 (42.1%) in the usual care group for the hierarchical composite primary outcome, with a win ratio of 1.16 (95% CI, 1.02-1.33; P = .04). Individual wins for death were 19.1% vs 17.8%; duration of vital support, 26.4% vs 21.1%; and length of hospital stay, 3.4% vs 3.2% in the intervention vs usual care groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients with early septic shock, a personalized hemodynamic resuscitation protocol targeting capillary refill time was superior to usual care for the primary composite outcome, primarily due to a lower duration of vital support. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05057611.
2. Selective Decontamination of the Digestive Tract during Ventilation in the ICU.
In a large international cluster randomized trial, SDD did not reduce 90-day in-hospital mortality among mechanically ventilated ICU patients. Although patient-level microbiology suggested fewer bloodstream infections and fewer cultured antibiotic-resistant organisms with SDD, the ecologic noninferiority threshold for resistant organisms was not met.
Impact: This definitive trial informs a decades-long debate by showing no mortality benefit of SDD and raises unresolved ecological concerns, directly impacting ICU infection control policies.
Clinical Implications: Routine SDD to reduce mortality in ventilated ICU patients is not supported. Centers considering SDD must weigh potential reductions in bloodstream infections against uncertain ecological risks and the inability to confirm noninferiority regarding resistant organisms at the unit level.
Key Findings
- No difference in 90-day in-hospital mortality: 27.9% (SDD) vs 29.5% (standard care), OR 0.93 (95% CI 0.84–1.05; P=0.27).
- SDD group had fewer new bloodstream infections (adjusted mean difference −1.30 percentage points) and fewer cultured antibiotic-resistant organisms (−9.60 percentage points) at the patient level.
- In the ecologic assessment, noninferiority for new antibiotic-resistant organisms was not confirmed, leaving ecological safety unresolved.
Methodological Strengths
- Large, rigorous cluster randomized cross-over design across 26 ICUs with concurrent ecological surveillance.
- Prespecified patient-level and ecological outcomes allow balanced assessment of efficacy and potential harms.
Limitations
- Heterogeneity in standard care and antimicrobial ecology across sites may influence generalizability.
- Ecologic noninferiority was not achieved; longer-term or broader ecological consequences remain uncertain.
Future Directions: Further work should refine ecological endpoints and surveillance, evaluate targeted SDD strategies or alternatives, and assess antimicrobial stewardship interactions and cost-effectiveness.
BACKGROUND: Whether selective decontamination of the digestive tract (SDD) reduces mortality among patients undergoing mechanical ventilation and whether it adversely affects microbial ecology in the intensive care unit (ICU) remain unclear. In an earlier analysis of data from Australia, SDD did not result in a lower incidence of in-hospital death than standard care, but data from the full international trial are needed. METHODS: We randomly assigned ICUs in Australia and Canada to use SDD or to continue standard care for two 12-month periods in patients undergoing mechanical ventilation. Patients in the SDD group received specific oral and gastric antimicrobial interventions for the duration of ventilation and an intravenous antibiotic agent for the first 4 days after enrollment. All other patients in the ICU were included in an observational ecologic assessment. Previously reported data from Australia are now combined with data from Canada. The primary outcome was in-hospital death from any cause at 90 days. The secondary clinical outcomes, assessed at 90 days, were death in the ICU and the number of days alive and free of mechanical ventilation, ICU admission, and hospitalization. Microbiologic secondary outcomes included new positive cultures for bloodstream infections and antibiotic-resistant organisms. For the ecologic assessment, the microbiologic outcomes were tested for noninferiority (noninferiority margin, 2 percentage points). RESULTS: In this trial involving 20,000 patients in 26 ICUs, 9289 patients were enrolled in the randomized trial and 10,711 were included in the ecologic assessment. At 90 days, 1175 of 4215 patients (27.9%) in the SDD group and 1494 of 5065 (29.5%) in the standard-care group had died before hospital discharge (odds ratio, 0.93; 95% confidence interval [CI], 0.84 to 1.05; P = 0.27). New bloodstream infections occurred in 4.9% of the patients in the SDD group and in 6.8% of those in the standard-care group (adjusted mean difference, -1.30 percentage points; 95% CI, -2.55 to -0.05); antibiotic-resistant organisms were cultured in 16.8% and 26.8%, respectively (adjusted mean difference, -9.60 percentage points; 95% CI, -12.40 to -6.80). In the ecologic assessment, noninferiority of SDD was not confirmed for the development of new antibiotic-resistant organisms. Adverse events considered to be related to SDD or standard care were reported in 12 patients (0.3%) in the SDD group and in no patients in the standard-care group. Serious adverse events occurred in 47 patients (1.1%) and 59 patients (1.2%), respectively. CONCLUSIONS: Among critically ill patients undergoing mechanical ventilation, SDD did not result in a lower incidence of in-hospital death than standard care. (Funded by the National Health and Medical Research Council of Australia and the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT02389036.).
3. Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score.
Using over 3.3 million ICU encounters across 9 countries, SOFA-2 updated variables and thresholds for six organ systems and improved AUROC (0.79 vs 0.77 for legacy SOFA) on ICU day 1, with sustained predictive validity through day 7. Gastrointestinal and immune subscores were not incorporated due to insufficient data and content validity.
Impact: SOFA-2 modernizes the most widely used organ dysfunction score, aligning it with contemporary ICU practices and improving predictive performance, with potential to standardize endpoints and risk adjustment in trials and clinical care.
Clinical Implications: SOFA-2 can be adopted for early risk stratification, prognosis, and trial enrollment/stratification, reflecting current organ support modalities. Implementation should consider training and EHR integration; cross-setting calibration may be necessary.
Key Findings
- SOFA-2 improved AUROC on ICU day 1 to 0.79 (95% CI 0.76–0.81) versus legacy SOFA 0.77 (95% CI 0.74–0.81).
- Updated variables and thresholds across brain, respiratory, cardiovascular, liver, kidney, and hemostasis systems; predictive validity maintained across ICU days 1–7.
- Gastrointestinal and immune subscores were not included due to insufficient data and content validity.
Methodological Strengths
- Massive federated, multicountry datasets for development and external validation.
- Combined expert consensus (modified Delphi) with data-driven thresholding for content and predictive validity.
Limitations
- Observational data cannot establish causal impacts of score-guided decisions.
- Gastrointestinal and immune dysfunctions were not incorporated; implementation and calibration needs remain.
Future Directions: Prospective validation for clinical decision support, evaluation of responsiveness to interventions, and assessment of global calibration across resource settings.
IMPORTANCE: Acute dysfunction of vital organs is the hallmark of critical illness. The Sequential Organ Failure Assessment (SOFA) score, the most widely adopted approach to describe organ dysfunction, has not been updated in 30 years and therefore may not appropriately capture current clinical practice and outcomes. OBJECTIVES: To inform the data-driven component of an updated score (SOFA-2) in varied geographical and resource settings (stages 6-8) after expert input via a modified Delphi process (stages 1-5). DESIGN, SETTING, AND PARTICIPANTS: A federated analysis was performed on data collected from adult patients admitted to 1319 intensive care units (ICUs) in 9 countries (Australia, Austria, Brazil, France, Italy, Japan, Nepal, New Zealand, United States) between 2014 and 2023. Four representative multicenter cohorts containing data from 2 098 356 patients were used for data-driven score development and internal validation. External validation was performed on 6 cohorts containing data from 1 241 114 patients. MAIN OUTCOMES AND MEASURES: Content validity for organ dysfunction identified through the modified Delphi process should be reflected by predictive validity using the area under the receiver operating characteristic (AUROC) curve of the score measured on the first ICU day (higher scores indicate worse organ dysfunction). RESULTS: Of 3.34 million patient encounters, 270 108 (8.1%) died in the ICU (range, 4.5% to 20.5% across the 10 cohorts). SOFA-2 modified the 6 organ systems of the original SOFA score (brain, respiratory, cardiovascular, liver, kidney, hemostasis), including new variables and revised thresholds that better describe the organ dysfunction distribution from 0 to 4 points and their associated mortality (SOFA-2 AUROC, 0.79; 95% CI, 0.76-0.81; SOFA-1 AUROC, 0.77; 95% CI, 0.74-0.81). Evaluation of sequential SOFA-2 data from ICU day 1 to day 7 maintained its predictive validity. Insufficient data and lack of content validity precluded incorporation of gastrointestinal and immune dysfunction scores into SOFA-2. CONCLUSIONS AND RELEVANCE: The SOFA-2 score, updated to include contemporary organ support treatments and new score thresholds, describes organ dysfunction in a large, geographically and socioeconomically diverse population of critically ill adults.